Reticulate Acropigmentation of Kitamura (RAK): A Comprehensive Disease Characterization Report

Disease: Reticulate Acropigmentation of Kitamura (RAK; RAPK; Kitamura disease) MONDO ID: MONDO:0014234 · OMIM: #615537 · Causal gene: ADAM10 (HGNC:188; NCBI Gene 102; UniProt O14672; a disintegrin and metalloproteinase domain-containing protein 10) Category: Mendelian, autosomal dominant

Note on disease identity: The name "Reticulate Acropigmentation of Kitamura" is correctly matched to ADAM10. It should not be confused with the clinically similar Dowling-Degos disease (KRT5/POFUT1/POGLUT1/PSENEN/GLMN) or dyschromatosis symmetrica hereditaria (ADAR1), which are distinct genetic entities within the overlapping reticulate-pigmentary-disorder spectrum.

Summary

Reticulate Acropigmentation of Kitamura (RAK) is a rare, autosomal-dominant pigmentary genodermatosis caused by heterozygous loss-of-function variants in ADAM10, the gene encoding the zinc-metalloprotease and ectodomain sheddase ADAM10. First described by Kitamura in Japan in 1943, the disorder manifests before puberty as reticulate (net-like), slightly depressed, brown pigmented macules concentrated on the dorsa of the hands and feet. Over years the pigmentation extends proximally to the limbs and trunk, and characteristic palmar pits and breaks in the epidermal ridge pattern (dermatoglyphic interruptions) develop. It is a benign, lifelong, cosmetically significant condition with a normal life expectancy and no systemic organ failure in the great majority of patients.

The central molecular insight, established by whole-exome sequencing of a RAK pedigree in 2013, is that RAK results from ADAM10 haploinsufficiency. ADAM10 is the principal Site-2 (S2) sheddase that activates Notch signaling in the epidermis. Reduced ADAM10 activity is inferred to lower keratinocyte and melanocyte Notch signaling, dysregulating epidermal differentiation and melanocyte homeostasis. Histopathology shows epidermal atrophy, elongated rete ridges laden with melanin, an increased number of active (dopa-positive) basal melanocytes, and enhanced melanosome transfer to keratinocytes — together producing the reticulate hyperpigmentation. This Notch-centric mechanism places RAK within a larger spectrum of reticulate pigmentary disorders that share disruption of Notch processing/glycosylation genes, most notably Dowling-Degos disease (DDD; KRT5, POFUT1, POGLUT1, PSENEN, GLMN).

RAK predominantly affects East Asian (Japanese, Chinese) populations, though cases occur worldwide. Diagnosis rests on clinical and histopathologic recognition supported by ADAM10 genetic testing, which is the most reliable way to distinguish RAK from clinically overlapping reticulate disorders. No curative or disease-modifying therapy exists; treatment is limited to inconsistently effective cosmetic measures (topical/oral retinoids, laser). The principal disease model is the mouse epidermal (K14-Cre) Adam10 conditional knockout, which recapitulates epidermal Notch loss-of-function; global Adam10 knockout is embryonic lethal owing to Notch failure. No naturally occurring animal counterpart of RAK has been described.

1. Disease Information

RAK is a hereditary reticulate pigmentary disorder (RPD) of the acral skin. The causal gene is ADAM10. Key identifiers:

The disease-level information in this report derives from aggregated disease-level resources and primary case reports / case series, not from individual EHR datasets. RAK was first described by Kitamura et al. in 1943 (PMID: 40950988).

2. Etiology

Primary cause — genetic. RAK is a monogenic Mendelian disorder caused by heterozygous loss-of-function variants in ADAM10. Whole-exome sequencing of a RAK family, followed by Sanger sequencing of four additional unrelated patients, identified five heterozygous ADAM10 mutations — three truncating, one splice-site, and one missense — with no mutations in KRT5 (the Dowling-Degos gene), establishing RAK as a genetically distinct entity (PMID: 23666529). "A mutation in ADAM10 encoding a zinc metalloprotease… was identified in the RAK family."

Genetic risk factors. The causal variants themselves are the risk factor; inheritance is autosomal dominant with high penetrance. No additional susceptibility loci or validated modifier genes have been defined.

Environmental / lifestyle risk factors. None established. RAK is a constitutive genetic disorder; no toxin, infection, diet, or occupational exposure is known to cause or trigger it. Pigmentation is lifelong and not clearly photo-driven, though sun-exposed acral sites are prominently involved.

Protective factors. No genetic or environmental protective factors are known.

Gene–environment interactions. None demonstrated.

3. Phenotypes

RAK phenotypes are primarily physical manifestations / clinical signs of the skin.

Characteristics. Onset is pre-pubertal/childhood. Severity is mild–moderate and cosmetic; the course is chronic, slowly progressive, and non-remitting, with proximal spread over years. The acral reticulate pigmentation, palmar pits, and dermatoglyphic breaks are the core, highly frequent features; skeletal and gingival anomalies are exceptional.

Key quotations: "The characteristic skin lesions are reticulate, slightly depressed pigmented macules mainly affecting the dorsa of the hands and feet, which first appear before puberty and subsequently expand to the proximal limb and the trunk" (PMID: 23666529); "hyperpigmented macules or papules that may interrupt the dermatoglyphics with extra-dermatological manifestations" (PMID: 35978738). Bony anomalies (absent terminal phalanges of the 2nd–4th toes) were reported in a single case (PMID: 8973039).

Quality of life. Impact is cosmetic/psychosocial rather than functional or life-threatening; no disease-specific QoL instrument data exist.

4. Genetic / Molecular Information

Causal gene: ADAM10 (chromosome 15q21.3), encoding a zinc-dependent transmembrane metalloprotease ("a disintegrin and metalloproteinase domain-containing protein 10").

Pathogenic variants. Reported RAK variants are predominantly loss-of-function: truncating (nonsense/frameshift), splice-site, and missense. In the defining study: "We identified a total of three truncating mutations, a splice site mutation and a missense mutation in ADAM10" (PMID: 23666529). Additional novel ADAM10 mutations have since been reported in individual RAK cases, including functional-implication studies (PMID: 29192958; PMID: 26892935; PMID: 30488468).

• Variant classification: pathogenic / likely pathogenic (ACMG), consistent with haploinsufficiency.
• Variant type/class: nonsense, frameshift (truncating), splice-site, missense.
• Allele frequency: private/family-specific; not common polymorphisms (ultra-rare).
• Origin: germline, autosomal dominant.
• Functional consequence: loss of function / haploinsufficiency (reduced functional ADAM10).

Modifier genes / epigenetics / chromosomal abnormalities. No validated modifiers, epigenetic marks, or chromosomal rearrangements are described for RAK.

Spectrum context. RAK is genetically distinct from Dowling-Degos disease, whose causal genes are KRT5, POFUT1, POGLUT1, PSENEN, and GLMN (PMID: 40674458). POFUT1 and POGLUT1 glycosylate Notch, and PSENEN/NCSTN are γ-secretase subunits — all converging on Notch, as does ADAM10 (PMID: 24387993; PMID: 37665193).

5. Environmental Information

No environmental factors, lifestyle factors, or infectious agents are implicated in RAK. It is a constitutive monogenic disorder. (ADAM10 is notably the cellular receptor exploited by Staphylococcus aureus α-toxin and participates in skin-microbiome regulation, but these are ADAM10 biology findings, not RAK triggers — PMID: 30324336; PMID: 34582748.)

6. Mechanism / Pathophysiology

Ordered causal chain

1. A heterozygous loss-of-function ADAM10 variant (truncating, splice-site, or missense) results in reduced functional ADAM10 protein (haploinsufficiency). [Demonstrated — human genetics, 23666529]
2. Reduced ADAM10 leads to decreased Site-2 ectodomain shedding of the Notch receptor in epidermal keratinocytes and melanocytes. [Demonstrated in mouse epidermis; inferred for human RAK — 21205794]
3. Decreased Notch shedding results in less generation of the Notch intracellular domain (NICD) and reduced Notch signaling. [Demonstrated — 21205794]
4. Reduced epidermal Notch signaling leads to dysregulated keratinocyte differentiation (epidermal atrophy, elongated rete ridges) and, in parallel, altered melanocyte/melanocyte-precursor homeostasis. [Branch — keratinocyte arm demonstrated in mouse; melanocyte arm inferred — 21205794, 25705850]
5. Melanocyte dysregulation results in an increased number of active (dopa-positive) basal melanocytes and enhanced transfer of melanosomes to surrounding keratinocytes. [Demonstrated — human histology/ultrastructure, 3994414]
6. These cellular changes manifest as pre-pubertal, slowly progressive, bilateral acral reticulate hyperpigmentation with palmar pits and dermatoglyphic breaks. [Demonstrated — clinical, 23666529]

ADAM10 LoF variant (germline, heterozygous)
        │  haploinsufficiency
        ▼
Reduced ADAM10 Site-2 sheddase activity
        │
        ▼
↓ Notch shedding → ↓ NICD → ↓ epidermal Notch signaling
        │
        ├──────────────┬───────────────────────────┐
        ▼              ▼                           ▼
Keratinocyte      Melanocyte / MC-precursor    Epidermal barrier/
differentiation   homeostasis dysregulated     adnexal changes
dysregulated      (↑ active basal              (modeled in mouse cKO)
(atrophy, long    melanocytes, ↑ melanosome
rete ridges)      transfer to keratinocytes)
        │              │
        └──────┬───────┘
               ▼
   Acral reticulate hyperpigmentation + palmar pits + dermatoglyphic breaks

Supporting detail

• Molecular pathway: Notch signaling is the central axis. ADAM10 is "the major Site-2 processing enzyme for Notch in the epidermis in vivo, and thus… a central regulator of skin development and maintenance," and in its absence "Notch processing is indeed strongly reduced resulting in decreased levels of Notch intracellular domain fragment and functional Notch signaling" (PMID: 21205794). Suggested GO terms: GO:0007219 (Notch signaling pathway), GO:0006509 (membrane protein ectodomain proteolysis), GO:0004222 (metalloendopeptidase activity).
• Protein dysfunction: ADAM10 is a promiscuous α-secretase/sheddase; "ADAM10 was found to exert many additional functions, cleaving about 100 different membrane proteins" (PMID: 37218105). Among its ~100 substrates (Notch, E-/N-cadherin, APP, ephrins, cytokine receptors), Notch is the essential one whose loss is lethal: "the even earlier fatal effects of ADAM10 deficiency exhibit key features of disabled Notch signalling and possibly also cadherin processing defects" (PMID: 18393804).
• Cellular processes: melanocyte survival/proliferation and melanosome transfer. "Inhibition of Notch signaling reduced the proliferation of NCSC-like cells, induced cell death" (PMID: 25705850). The pigment mechanism is cell-biological: "the hyperpigmentation of RAPK is due to increased number of active melanocytes and to increased transfer of melanosomes to surrounding keratinocytes" (PMID: 3994414).
• Cell types (CL): keratinocyte (CL:0000312), melanocyte (CL:0000148), epidermal/melanocyte stem cells.
• Subcellular (GO cellular component): melanosome (GO:0042470), plasma membrane (GO:0005886).

7. Anatomical Structures Affected

• Organ: skin (UBERON:0002097), the sole primary organ affected. No secondary systemic organ involvement in typical disease.
• Body system: integumentary system (UBERON:0002416).
• Regional sites: dorsum of hand (UBERON:0003401) and dorsum of foot (UBERON:0003402); palms and soles (palmar pits); later proximal limbs and trunk.
• Tissue/cell: epidermis (UBERON:0001003) — epithelial tissue; affected cells are keratinocytes (CL:0000312) and melanocytes (CL:0000148) at the basal layer; adnexal structures (hair follicles, sebaceous glands) are affected in the mouse model but not clinically prominent in human RAK.
• Subcellular: melanosome (GO:0042470).
• Lateralization: bilateral and symmetric, acrally accentuated.

Histology: "epidermal atrophy, elongation of the rete ridges with large amounts of melanin, and an increased number of dopa-positive basal melanocytes" (PMID: 3994414).

8. Temporal Development

• Onset: pediatric, before puberty; insidious/chronic onset.
• Progression: slowly progressive — lesions begin acrally and extend proximally to limbs and trunk over years. No staging system; the disease is chronic and lifelong.
• Course pattern: progressive-then-stable hyperpigmentation; no spontaneous remission.
• Critical period: childhood/adolescence, when lesions emerge and spread.

"…first appear before puberty and subsequently expand to the proximal limb and the trunk" (PMID: 23666529).

9. Inheritance and Population

• Inheritance: autosomal dominant, high penetrance; the RAK/DDD spectrum shows "rare genodermatoses inherited as an autosomal dominant trait with variable penetrance" (PMID: 26955585).
• Penetrance/expressivity: high penetrance with variable expressivity (age of onset, extent of spread, rare skeletal associations).
• Epidemiology: extremely rare; no formal prevalence/incidence figures are established (ultra-rare). East Asian (Japanese, Chinese) predominance: "Reticulate acropigmentation of Kitamura (RAK) predominantly affects East Asian populations, though isolated cases and familial occurrences have been reported globally" (PMID: 40950988); "Japanese researchers Kitamura et al. first described this condition in 1943" (PMID: 40950988).
• Anticipation, germline mosaicism, founder effects, consanguinity, carrier frequency: not established/not applicable (dominant disorder; variants are private).
• Sex ratio / age distribution: no strong sex predilection reported; onset in childhood.

10. Diagnostics

Clinical/histopathologic diagnosis + genetic confirmation.

• Dermoscopy & clinical signs: reticulate, slightly depressed brown macules on dorsal hands/feet; pigmented palmar pits; dermatoglyphic breaks aid recognition (PMID: 32055533; PMID: 32055524; PMID: 23746125).
• Histopathology/IHC: epidermal atrophy, elongated melanin-laden rete ridges, increased dopa-positive basal melanocytes; EM shows melanosome complexes in keratinocytes and melanosome-filled dendrites (PMID: 3994414).
• Genetic testing (definitive): single-gene ADAM10 sequencing or exome/panel testing. Because features overlap heavily across RPDs, "each of these hereditary conditions possesses a unique genetic mutation, and genetic analysis is thus more useful in the diagnosis of these conditions" (PMID: 29201043); "The overlapping features often add confusion and cause delay in diagnosis" (PMID: 39139099).

Differential diagnosis (reticulate pigmentary disorders) with distinguishing genes:

(References: PMID: 29201043; PMID: 37372478; PMID: 39139099; PMID: 30692041.)

Screening: no newborn/population screening; cascade genetic testing within families is possible once a pathogenic ADAM10 variant is known.

11. Outcome / Prognosis

RAK is benign with a normal life expectancy and no disease-specific mortality. Morbidity is cosmetic/psychosocial only. The hyperpigmentation is chronic, lifelong, and slowly progressive without spontaneous remission. No validated prognostic biomarkers are needed, as the disease does not threaten survival or organ function. "all three having limited treatment options" characterizes the therapeutic outlook for RAK and overlapping RPDs (PMID: 38646262).

12. Treatment

No curative or disease-modifying therapy exists. Management is cosmetic and often disappointing:

• Topical: retinoids (adapalene), hydroquinone — inconsistent results. In clinically overlapping DDD, "The patient was unsuccessfully treated with adapalene gel and refused the recommended oral retinoid therapy, as well as laser therapy" (PMID: 36919394).
• Systemic: oral retinoids — generally unsuccessful.
• Device: laser (e.g., Er:YAG, Q-switched) — reported effective only in isolated cases.
• Supportive: photoprotection, cosmetic camouflage, psychosocial support.

No pharmacogenomic, gene, cell, RNA, or targeted therapies are approved or in trials for RAK. Suggested NCIT concepts: retinoid therapy (NCIT:C1909 class), laser therapy (NCIT:C15193). "all three having limited treatment options" is explicitly documented (PMID: 38646262).

13. Prevention

No primary prevention is possible for a constitutive genetic disorder. Genetic counseling is the principal preventive tool: autosomal dominant inheritance implies a 50% transmission risk to offspring. Once a family's pathogenic ADAM10 variant is identified, cascade testing, prenatal testing, or preimplantation genetic diagnosis are theoretically available but rarely pursued given the benign nature of the disease. No immunization, behavioral, or public-health interventions apply.

14. Other Species / Natural Disease

• Taxonomy / orthologs: ADAM10 is highly evolutionarily conserved — mouse Adam10 (NCBI Gene 11487), zebrafish adam10a/adam10b. Human ADAM10 is NCBI Gene 102.
• Natural disease: No naturally occurring reticulate acropigmentation has been reported in companion animals or wildlife (OMIA lists no RAK entry).
• Comparative biology: The ADAM10→Notch axis is deeply conserved, so mechanistic conclusions from mouse apply broadly; however, the specific human pigmentary phenotype has no documented animal counterpart.
• Transmission: not applicable (non-infectious, non-zoonotic).

15. Model Organisms

"K14-Cre driven epidermal Adam10 deletion leads to perinatal lethality, barrier impairment and absence of sebaceous glands" (PMID: 21205794).

Limitations of models: mouse epidermal knockouts are far more severe (lethal, barrier failure) than the mild human haploinsufficiency; crucially, no model reproduces the specific human acral reticulate hyperpigmentation, so models inform the ADAM10→Notch mechanism but not the pigmentary phenotype directly. No zebrafish/Drosophila/iPSC/organoid RAK-specific model is established.

Key Findings (with evidence)

1. ADAM10 loss-of-function causes RAK. WES of a RAK pedigree + Sanger of 4 unrelated patients found 5 heterozygous ADAM10 mutations (3 truncating, 1 splice, 1 missense); no KRT5 mutations — RAK is distinct from DDD (PMID: 23666529).
2. ADAM10 is the principal epidermal Site-2 Notch sheddase; its loss reduces NICD and Notch signaling and reproduces Notch-LoF skin phenotypes in mice (PMID: 21205794).
3. RAK belongs to a Notch-pathway reticulate pigmentary spectrum overlapping DDD (KRT5, POFUT1, POGLUT1, PSENEN, GLMN) — all Notch processing/glycosylation genes (PMID: 40674458; PMID: 24387993; PMID: 37665193).
4. Histopathology: epidermal atrophy, elongated melanin-laden rete ridges, increased active basal melanocytes, enhanced melanosome transfer (PMID: 3994414).
5. Clinical phenotype: pre-pubertal acral reticulate hyperpigmentation with dermatoglyphic breaks, palmar pits, rare skeletal anomalies (PMID: 23666529; PMID: 35978738; PMID: 8973039).
6. ADAM10 is a promiscuous sheddase (~100 substrates); Notch is the essential one whose loss is embryonic-lethal (PMID: 37218105; PMID: 18393804).
7. Epidemiology: extremely rare, East-Asian predominant, AD with variable penetrance/expressivity (PMID: 40950988; PMID: 26955585).
8. Diagnosis rests on clinical-dermoscopic-histologic correlation + ADAM10 genetic confirmation (PMID: 29201043; PMID: 39139099).
9. Notch regulates melanocyte/MC-stem-cell homeostasis, linking ADAM10 loss to altered pigmentation (PMID: 25705850).
10. Benign, chronic, limited-therapy disorder (PMID: 38646262; PMID: 36919394).
11. Mouse epidermal Adam10 cKO is the key model; no natural animal RAK (PMID: 21205794; PMID: 26522965).
12. Integrated causal model: ADAM10 haploinsufficiency → ↓ epidermal Notch → keratinocyte/melanocyte dysregulation → acral reticulate hyperpigmentation (PMID: 23666529; PMID: 21205794; PMID: 3994414).

Mechanistic Model / Interpretation

The twelve findings converge on a single, coherent causal narrative. RAK begins with a germline heterozygous ADAM10 loss-of-function allele. Because ADAM10 is the dominant Site-2 sheddase that activates Notch in the epidermis, halving its dose is sufficient to reduce Notch intracellular-domain generation and downstream Notch signaling. Notch is a master regulator of both keratinocyte differentiation and melanocyte homeostasis, so its attenuation branches into two coupled effects: aberrant keratinocyte differentiation (seen histologically as epidermal atrophy and elongated, melanin-laden rete ridges) and increased activity of basal melanocytes with enhanced melanosome transfer to keratinocytes. The net clinical readout is the slightly depressed, reticulate, acral hyperpigmentation with palmar pits and dermatoglyphic breaks. Critically, the same Notch axis — accessed through glycosylation (POFUT1, POGLUT1) or γ-secretase (PSENEN, NCSTN) — unifies the clinically overlapping Dowling-Degos spectrum, explaining why these disorders share reticulate pigmentation yet are genetically distinct.

The chain is firmly anchored at its endpoints (human genetics at the top; human histology and clinical phenotype at the bottom) but relies on mouse/in-vitro evidence for its middle steps (the quantitative reduction in Notch signaling and the keratinocyte/melanocyte response). This is the principal interpretive caveat: the Notch-reduction step is demonstrated in mouse epidermis and inferred, not directly measured, in human RAK skin.

Evidence Base

Evidence source types: human clinical genetics and histopathology (23666529, 3994414, 35978738, 8973039); mouse model (21205794, 34582748, 26522965); in vitro / mechanistic (25705850, 37218105, 18393804); reviews (30692041, 37372478, 40674458).

Limitations and Knowledge Gaps

• No direct human tissue proof that NICD/Notch signaling is reduced in RAK epidermis — the Notch-reduction step is inferred from the mouse model, not demonstrated in patient skin.
• Genotype–phenotype correlation is unknown: why haploinsufficiency produces a pigmentary, acral phenotype in humans while the mouse epidermal null is lethal and barrier-focused is unexplained. The mild human phenotype vs. severe mouse phenotype gap limits model translation.
• No formal epidemiology (prevalence/incidence) exists; estimates are impressionistic.
• Melanocyte-arm mechanism is partly inferred: the link from reduced keratinocyte/melanocyte Notch to "increased active melanocytes + melanosome transfer" is supported by histology (3994414) and Notch-melanocyte biology (25705850) but not by a RAK-specific functional melanocyte study.
• No modifier genes, epigenetic data, or therapeutics have been systematically investigated.

Proposed Follow-up Experiments / Actions

1. Patient-skin Notch readout: quantify NICD, HES1/HEY1, and ADAM10 protein in RAK lesional vs. non-lesional epidermis to directly test steps 2–3 of the causal chain.
2. RAK-relevant model: generate a melanocyte-specific or inducible heterozygous Adam10 mouse (or a human iPSC-derived keratinocyte–melanocyte co-culture / skin organoid carrying a patient ADAM10 LoF variant) to reproduce the pigmentary phenotype at physiologic haploinsufficiency.
3. Melanocyte functional assays: measure melanocyte activation (dopa positivity, tyrosinase), dendricity, and melanosome transfer under ADAM10 knockdown/Notch inhibition.
4. Genotype–phenotype registry: aggregate ADAM10 variants with age of onset, extent of spread, and rare skeletal/gingival features to define expressivity drivers.
5. Therapeutic exploration: test whether topical Notch-pathway modulators or targeted melanogenesis inhibitors improve pigmentation in controlled series, given the current therapeutic void.

Report compiled from a 5-iteration autonomous investigation; 12 confirmed findings; 44 papers reviewed.